Paul Newhouse
YOU?
Author Swipe
View article: Association of cholinergic integrity measured by [ <sup>18</sup> F]‐fluoroethoxybenzovesamicol with age and amyloid burden in adults with Down syndrome
Association of cholinergic integrity measured by [ <sup>18</sup> F]‐fluoroethoxybenzovesamicol with age and amyloid burden in adults with Down syndrome Open
Background Adults with Down syndrome (DS) are at increased risk for Alzheimer's disease (AD) due to APP triplication. Cholinergic system degeneration underlies many AD‐related cognitive deficits, but cholinergic integrity in adults with DS…
View article: Computerized Memory Enhancement using NeuroFlex for Patients with Mild Cognitive Impairment: Results of a Pilot and Feasibility Study
Computerized Memory Enhancement using NeuroFlex for Patients with Mild Cognitive Impairment: Results of a Pilot and Feasibility Study Open
Background The use of cognitive training as a therapeutic intervention for adults with Mild Cognitive Impairment (MCI) offers the potential for improved cognition without the adverse effects seen in many pharmacological trials. A novel cog…
View article: Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants
Safety, tolerability, pharmacokinetic and pharmacodynamic effects of the muscarinic M1 positive allosteric modulator VU0467319 for Alzheimer’s disease: a single ascending-dose study in healthy participants Open
The development of cholinergic neurotransmitter based cognitive enhancers for Alzheimer’s disease and other neuropsychiatric disorders have focused recently on allosteric modulation of specific muscarinic acetylcholine receptor (mAChR) sub…
View article: Brain cholinergic terminal density utilizing [<sup>18</sup>F]‐fluoroethoxybenzovesamicol PET in adults with Down's syndrome: Relationship to amyloid PET and cognitive performance
Brain cholinergic terminal density utilizing [<sup>18</sup>F]‐fluoroethoxybenzovesamicol PET in adults with Down's syndrome: Relationship to amyloid PET and cognitive performance Open
BACKGROUND Adults with Down syndrome (DS) have increased risk of Alzheimer's disease (AD). The cholinergic system declines in AD, underlying many cognitive deficits. We investigated the relationship between amyloid accumulation and choline…
View article: Resistance and resilience to Alzheimer's disease in Down syndrome
Resistance and resilience to Alzheimer's disease in Down syndrome Open
Due to the high prevalence of Alzheimer's disease (AD) in adults with Down syndrome (DS), trisomy 21 is now considered a genetic form of AD (DSAD). A better understanding of factors that can prevent or delay AD is vital to improve outcomes…
View article: Differences in cholinergic terminal density in adults with Down syndrome compared to neurotypical controls measured by [18F]-fluoroethoxybenzovesamicol positron emission tomography imaging
Differences in cholinergic terminal density in adults with Down syndrome compared to neurotypical controls measured by [18F]-fluoroethoxybenzovesamicol positron emission tomography imaging Open
Adults with Down syndrome are genetically predisposed to developing Alzheimer's disease after the age of 40. The cholinergic system, which is critical for cognitive functioning, is known to decline in Alzheimer's disease and although first…
View article: Relationship between electrophysiological performance during an incidental memory task and cholinergic integrity in a pilot study in adults with Down syndrome
Relationship between electrophysiological performance during an incidental memory task and cholinergic integrity in a pilot study in adults with Down syndrome Open
Background Adults with Down syndrome (DS) are at a high risk of developing Alzheimer’s disease (AD) due to the triplication of the amyloid precursor protein on chromosome 21. Despite the high incidence of AD within the DS population, there…
View article: Investigating the association between cholinergic integrity and amyloid burden using cholinergic anatomy and [<sup>18</sup>F]‐FEOBV PET in individuals with Down Syndrome from the ABC‐DS and TRC‐DS cohorts
Investigating the association between cholinergic integrity and amyloid burden using cholinergic anatomy and [<sup>18</sup>F]‐FEOBV PET in individuals with Down Syndrome from the ABC‐DS and TRC‐DS cohorts Open
Background Adults with Down Syndrome (DS) have the highest risk of developing Alzheimer’s disease (AD) worldwide. Triplication of the amyloid precursor protein gene on chromosome 21 results in early amyloid accumulation and Alzheimer’s pat…
View article: Assessing the association between cholinergic integrity and cognitive performance in adults with Down Syndrome using cholinergic anatomy and [<sup>18</sup>F]‐FEOBV PET
Assessing the association between cholinergic integrity and cognitive performance in adults with Down Syndrome using cholinergic anatomy and [<sup>18</sup>F]‐FEOBV PET Open
Background Triplication of the amyloid precursor protein in individuals with Down Syndrome (DS) produces an increased risk for the development of Alzheimer's disease (AD). Declining cholinergic integrity plays a role in the cognitive defic…
View article: Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation Open
Importance: Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer Association (AA) criteria for AD furthers this direction. Howev…
View article: Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation Open
Importance Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer’s Association (AA) criteria for AD furthers this direction. Howe…
View article: Age-Related Changes in the Cholinergic System in Adults with Down Syndrome Assessed Using [<sup>18</sup>F]-Fluoroethoxybenzovesamicol Positron Emission Tomography Imaging
Age-Related Changes in the Cholinergic System in Adults with Down Syndrome Assessed Using [<sup>18</sup>F]-Fluoroethoxybenzovesamicol Positron Emission Tomography Imaging Open
Adults with Down syndrome are genetically predisposed to developing Alzheimer’s disease after the age of 40. The cholinergic system, which is critical for cognitive functioning, is known to decline in Alzheimer’s disease and although first…
View article: User-Centered Design of Socially Assistive Robotic Combined with Non-Immersive Virtual Reality-based Dyadic Activities for Older Adults Residing in Long Term Care Facilities
User-Centered Design of Socially Assistive Robotic Combined with Non-Immersive Virtual Reality-based Dyadic Activities for Older Adults Residing in Long Term Care Facilities Open
Apathy impairs the quality of life for older adults and their care providers. While few pharmacological remedies exist, current non-pharmacologic approaches are resource intensive. To address these concerns, this study utilizes a user-cent…
View article: Effect of estradiol with or without micronized progesterone on cholinergic-related cognitive performance in postmenopausal women
Effect of estradiol with or without micronized progesterone on cholinergic-related cognitive performance in postmenopausal women Open
Introduction Women are at a higher risk of developing Alzheimer’s disease (AD), and the decline in estrogens post-menopause is thought of as a factor increasing this risk. Estradiol (E2) is important in supporting cholinergic neuronal inte…
View article: Effects of open-label transdermal nicotine antidepressant augmentation on affective symptoms and executive function in late-life depression
Effects of open-label transdermal nicotine antidepressant augmentation on affective symptoms and executive function in late-life depression Open
The study was registered with clinicaltrials.gov (NCT04433767).
View article: A Pilot Study Assessing Central Cholinergic Integrity in Individuals with Down Syndrome Using [<sup>18</sup>F]‐FEOBV PET and Basal Forebrain Cholinergic Anatomy
A Pilot Study Assessing Central Cholinergic Integrity in Individuals with Down Syndrome Using [<sup>18</sup>F]‐FEOBV PET and Basal Forebrain Cholinergic Anatomy Open
Background Down Syndrome (DS) individuals express an extra copy of chromosome 21, which contains the gene for APP, producing a higher risk of developing Alzheimer’s Disease (AD). By 40 years old, amyloid plaques and tau neurofibrillary tan…
View article: Overcoming Recruitment Challenges and Increasing Representation and Diversity of Participation in Early MCI Clinical Trials: The MIND Study Experience
Overcoming Recruitment Challenges and Increasing Representation and Diversity of Participation in Early MCI Clinical Trials: The MIND Study Experience Open
Background The MIND ( M emory I mprovement with N icotine D osing) study is an ongoing trial to determine whether long‐term transdermal nicotine treatment results in sustained cognitive improvement and attenuation of cognitive decline in p…
View article: Multifaceted approach to minority recruitment for participants in Alzheimer’s Disease research studies
Multifaceted approach to minority recruitment for participants in Alzheimer’s Disease research studies Open
Background Alzheimer’s Disease (AD) disproportionately affects Black and Hispanic adults as compared to white adults, yet 75% of those who participate in AD research are white (1,2,3). Without the full participation of under‐represented gr…
View article: Long‐term nicotine treatment of mild cognitive impairment (The MIND Study): Baseline characteristics and study progress
Long‐term nicotine treatment of mild cognitive impairment (The MIND Study): Baseline characteristics and study progress Open
Background Cognitive decline in AD/MCI is related to loss of cholinergic neurons. However, inhibition of acetylcholine degradation has not slowed progression. Treatment directly targeting nicotinic cholinergic receptors may be more helpful…
View article: Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairment
Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairment Open
Purpose Chemotherapy-related cognitive impairment (CRCI) is a distressing and increasingly recognized long-term sequela reported by breast cancer patients following cancer treatment. There is an urgent but unmet clinical need for treatment…
View article: In vivo cholinergic system integrity and cognition using [18F]‐FEOBV PET in healthy postmenopausal women: a pilot study
In vivo cholinergic system integrity and cognition using [18F]‐FEOBV PET in healthy postmenopausal women: a pilot study Open
Background Women are at a higher risk of developing Alzheimer’s disease (AD), and a possible reason for this may be the effects of estrogen depletion and cholinergic system activity following menopause. The investigational radiotracer [18F…
View article: M<sub>1</sub> muscarinic acetylcholine receptor positive allosteric modulators do not disrupt sleep in aged cynomolgus macaques
M<sub>1</sub> muscarinic acetylcholine receptor positive allosteric modulators do not disrupt sleep in aged cynomolgus macaques Open
Background Age‐related changes in sleep may directly contribute to cognitive dysfunction and underlying pathological progression contributing to Alzheimer’s Disease or related dementias (AD/ADRDs). While acetylcholinesterase inhibitors (AC…
View article: Estradiol treatment in young postmenopausal women with self‐reported cognitive complaints: Effects on cholinergic‐mediated cognitive performance
Estradiol treatment in young postmenopausal women with self‐reported cognitive complaints: Effects on cholinergic‐mediated cognitive performance Open
Objective Older women are at increased risk of developing Alzheimer's disease compared to men. One proposed reason is that following menopause there is a decline in estrogens. Estrogens are important for cholinergic functioning and attenua…
View article: EEG as a Functional Marker of Nicotine Activity: Evidence From a Pilot Study of Adults With Late-Life Depression
EEG as a Functional Marker of Nicotine Activity: Evidence From a Pilot Study of Adults With Late-Life Depression Open
Late-life depression (LLD) is a debilitating condition that is associated with poor response to antidepressant medications and deficits in cognitive performance. Nicotinic cholinergic stimulation has emerged as a potentially effective cand…
View article: Cognitive Health After MenoPause (CHAMP) Study: A study of the health of the cholinergic system and risk factors for future cognitive decline in postmenopausal women aged 50‐70
Cognitive Health After MenoPause (CHAMP) Study: A study of the health of the cholinergic system and risk factors for future cognitive decline in postmenopausal women aged 50‐70 Open
Background Menopause is associated with changes in hormone balances, and also to cognition in some women. These changes have been proposed to lead to an increased risk of developing Alzheimer’s disease (AD). However, there is not a clear u…